WEBINAR SERIES

  1. Home
  2. Webinars
  3. February 2022

ISLH Webinar: Overview of Statistical Methods for the Routine Hematology Laboratory

Speaker

Dr. Ruth Padmore

"Overview of Statistical Methods for the Routine Hematology Laboratory"

Learning Objectives:

  • Be informed of mathematical calculations and statistical methods for the routine hematology laboratory

  • Be knowledgeable of their application in day-to-day practice





    • Watch the Webinar





    Answers to Questions from Live Webinar

    Below is a list of questions received from the live webinar attendees. Click on any question to reveal the speaker's response.

    NEW QUESTION/ANSWER

    It is common to see necrosis in cHL, hard to put a number on it offhand.

    NEW QUESTION/ANSWER

    Classic in the 2017 WHO

    NEW QUESTION/ANSWER

    It can be expressed in both CHL and ALCL so it may not be reliable.

    NEW QUESTION/ANSWER

    CD15, CD30, CD20, PAX5, OCT2, BOB1 and CD45 can be helpful.

    NEW QUESTION/ANSWER

    I have never seen this.

    NEW QUESTION/ANSWER

    No, there is no clinical role for this at present.

    NEW QUESTION/ANSWER

    This would be highly unusual

    NEW QUESTION/ANSWER

    I don’t have any experience with J chain but is usually negative in RS-cells. MUM1 is typically positive but not specific.

    NEW QUESTION/ANSWER

    No

    NEW QUESTION/ANSWER

    Yes. J-chain and MEF2B have been reported to be useful as well. PMID: 28851661

    NEW QUESTION/ANSWER

    I don’t think it is particularly helpful, some cases of cHL may have rearranged IGH

    NEW QUESTION/ANSWER

    No

    NEW QUESTION/ANSWER

    I don’t find it that helpful

    NEW QUESTION/ANSWER

    There has been some data to suggest it is prognostic.

    NEW QUESTION/ANSWER

    It does not appear to commonly result in loss of CD30 expression in follow-up biopsy but I don’t believe this has been extensively studied.

    NEW QUESTION/ANSWER

    Yes, for T-cell lymphomas including cutaneous T-cell lymphomas it is reasonable to report the % positive tumor cells because some trials that resulted in the approval of brentuximab used specific cutoffs.